What to Know About Diabetes and the Risk of Silent Heart Attacks
At first it seemed like a routine call—something the paramedics had dealt with countless times before. A man in his mid-50s was having a heart attack, and his physician had called for emergency support. But when the paramedics arrived, the physician pulled them aside and told them something peculiar: the man had no cardiovascular symptoms whatsoever.
The man had come to his doctor’s office because he’d woken early the previous morning sweating and with a sharp pain in his left wrist. These symptoms had quickly subsided and he’d gone back to sleep. Later, after going about his day, he’d visited...
Source: TIME: Health - November 4, 2022 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate heart health Source Type: news
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
Pratteln, Switzerland, and Rockville, MD, USA, October 27, 2022– Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce that they have completed the rolling submission of a new drug application (NDA) to the U.S. Food... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - October 27, 2022 Category: Drugs & Pharmacology Source Type: news
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two yearsInitiation of OCREVUS as first-line treatment reduces relapses,hospitalisations and costs compared with using OCREVUS in second-line settingNine-year long-term safety data for OCREVUS further reinforcefavourable benefit-risk profile; more than 250,000 people have been treated globallyPregnancy outcomes reported for more than 2,000 women with multiple sclerosis (MS) treated with OCREVUS do not suggest an increased risk of adverse pregnancy and infant outco...
Source: Roche Media News - October 26, 2022 Category: Pharmaceuticals Source Type: news
Early treatment with Roche's OCREVUS leads to reduced disease progression and healthcare costs; nine-year safety data reinforce favourable benefit-risk profile
77% of early-stage relapsing-remitting multiple sclerosis (RRMS) patients who had not received prior treatment achieved no evidence of disease activity (NEDA) at two yearsInitiation of OCREVUS as first-line treatment reduces relapses,hospitalisations and costs compared with using OCREVUS in second-line settingNine-year long-term safety data for OCREVUS further reinforcefavourable benefit-risk profile; more than 250,000 people have been treated globallyPregnancy outcomes reported for more than 2,000 women with multiple sclerosis (MS) treated with OCREVUS do not suggest an increased risk of adverse pregnancy and infant outco...
Source: Roche Investor Update - October 26, 2022 Category: Pharmaceuticals Source Type: news
Highlights in Corneal Disorders From AAO 2022 Highlights in Corneal Disorders From AAO 2022
Key data in corneal disorders from AAO include a nontransplant therapy for Fuchs dystrophy, data on corneal adverse events from a myeloma drug, and positive data on lotilaner for Demodex blepharitis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 21, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Media News - October 19, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Investor Update - October 19, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Group salesup 2%[1] at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye diseases)US approval...
Source: Roche Investor Update - October 18, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche records solid results for the first nine months of 2022
Basel, 18 October 2022Group salesup 2%1 at constant exchange rates (CER) and 1% in Swiss francs; as expected, significantly lower COVID-19-related sales in both divisions in the third quarterSales in the Pharmaceuticals Divisionat the previous year ’s level with significantly lower sales of COVID-19-related products (Ronapreve and Actemra/RoActemra) and losses to biosimilars, offset by strong growth of newer medicinesSales in the Diagnostics Divisionrise 6%; base business remains strong; as expected, demand for COVID-19 tests sharply down in third quarterHighlights in the third quarter:EU approval forVabysmo (severe eye ...
Source: Roche Media News - October 18, 2022 Category: Pharmaceuticals Source Type: news
Baltimore startup Vita Therapeutics raises $31M to advance treatment for genetic diseases
Baltimore's Vita Therapeutics announced the completion of a $31 million series B funding round on Wednesday, propelling the cell therapy company toward a clinical trial and the development of new treatments for rare diseases.
The round, led by Cambrian BioPharma and Solve FSHD, will pay for the studies Vita needs for a human clinical trial for VTA-100, a treatment for a genetic disease called limb-girdle muscular dystrophy that weakens the muscles of a patient's arms and legs. CEO Douglas Falk … (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - October 12, 2022 Category: Biotechnology Authors: Matt Hooke Source Type: news
Dyne founder heads up new RNA-editing startup
The founder of muscular dystrophy company Dyne Therapeutics Inc. is heading up a new venture, this time focused on the burgeoning field of RNA medicines. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - October 12, 2022 Category: American Health Authors: Rowan Walrath Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Media News - October 12, 2022 Category: Pharmaceuticals Source Type: news
Positive new data for Roche ’s Evrysdi in largest trial ever undertaken in patients with previously-treated spinal muscular atrophy (SMA)
New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatalThe JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trialLonger-term safety data consistent with that previously seen in earlier trials and low study drop-out rateEvrysdi has proven efficacy in babies, children and adults, with more than 7,000 patients treated to date worldwideBasel, 12 October 2022- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new two-year data from the JEWELFISH study evaluating Evrysdi ® (risdiplam) in...
Source: Roche Investor Update - October 12, 2022 Category: Pharmaceuticals Source Type: news
Gene Therapy Shows Potential for RPE65-Related Retinal Dystrophy Gene Therapy Shows Potential for RPE65-Related Retinal Dystrophy
The rare genetic retinal disorder results in severe visual impairment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 6, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news
Improving lives means more than putting money in people ’ s pockets, says UNISON general secretary
Unleashing the potential in everyone and using the power of the collective to achieve that are the themes running through the annual Jimmy Reid Foundation lecture to be delivered by UNISON general secretary Christina McAnea in Glasgow later today (Thursday).
She will say: “It’s a huge privilege to be honouring one of Glasgow’s finest heroes. I heard Jimmy speak in the early 1970s in the Glasgow City halls. The place was packed to the rafters. I was about 15.
“He spoke for over an hour, but time passed in a flash. He had no notes as he walked up and down the stage, talking eloquently, with great passion. His dee...
Source: UNISON Health care news - October 6, 2022 Category: UK Health Authors: Fatima Ayad Tags: News Press release Christina McAnea Source Type: news
